Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure

Reza Mohebi; Yuxi Liu; G Michael Felker; Jonathan H Ward; Ileana L Piña; Javed Butler; Scott D Solomon; James L Januzzi

doi:10.1161/JAHA.122.029229

Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure

J Am Heart Assoc. 2023 Apr 18;12(8):e029229. doi: 10.1161/JAHA.122.029229. Epub 2023 Apr 12.

Authors

Reza Mohebi^{1

2}, Yuxi Liu^{1

2}, G Michael Felker³, Jonathan H Ward⁴, Ileana L Piña^{5

6

7}, Javed Butler^{8

9}, Scott D Solomon^{2

10

11}, James L Januzzi^{1

2

11}

Affiliations

¹ Massachusetts General Hospital Boston MA.
² Harvard Medical School Boston MA.
³ Duke University Medical Center and Duke Clinical Research Institute Durham NC.
⁴ Novartis Pharmaceuticals East Hanover NJ.
⁵ Central Michigan University Midland MI.
⁶ Population & Quantitative Health Sciences Center Case Western University Cleveland OH.
⁷ Center for Devices and Radiological Health U.S. Food and Drug Administration Silver Spring MD.
⁸ University of Mississippi Medical Center Jackson MS.
⁹ Baylor Scott and White Heath Dallas TX.
¹⁰ Brigham and Women's Hospital Boston MA.
¹¹ Baim Institute for Clinical Research Boston MA.

No abstract available

Keywords: cardiac remodeling; heart failure; left ventricular ejection fraction; natriuretic peptide; sacubitril/valsartan.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Angiotensin Receptor Antagonists / therapeutic use
Biphenyl Compounds
Drug Combinations
Heart Failure* / drug therapy
Humans
Stroke Volume
Valsartan

Substances

sacubitril
Valsartan
Biphenyl Compounds
Drug Combinations
Angiotensin Receptor Antagonists